# A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

Study · id `cardio:ct-nct04936035` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04936035](<https://clinicaltrials.gov/study/NCT04936035>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04936035

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 394 participants.

## Technical summary

Registry record NCT04936035. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-07 (actual); primary completion 2023-04-04 (actual). Results posted on 2024-12-27.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 394 participants (enrolled count; ClinicalTrials.gov record NCT04936035, source copy `cardio:ctgov-nct04936035-2025-12-23`, retrieved 2026-10-26)
- Started: 2021-07-07 (actual) (ClinicalTrials.gov record NCT04936035, source copy `cardio:ctgov-nct04936035-2025-12-23`, retrieved 2026-10-26)
- Primary completion: 2023-04-04 (actual) (ClinicalTrials.gov record NCT04936035, source copy `cardio:ctgov-nct04936035-2025-12-23`, retrieved 2026-10-26)
- Completion: 2024-12-05 (actual) (ClinicalTrials.gov record NCT04936035, source copy `cardio:ctgov-nct04936035-2025-12-23`, retrieved 2026-10-26)
- Results first posted: 2024-12-27 (ClinicalTrials.gov record NCT04936035, source copy `cardio:ctgov-nct04936035-2025-12-23`, retrieved 2026-10-26)
- Countries: United States; Canada; Puerto Rico; Ukraine; United Kingdom (ClinicalTrials.gov record NCT04936035, source copy `cardio:ctgov-nct04936035-2025-12-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04936035-2025-12-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension
- Acronym: KARDIA-1
- Condition: Hypertension
- Intervention (Drug): Placebo
- Intervention (Drug): ALN-AGT01
- Lead sponsor: Alnylam Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Alnylam Pharmaceuticals (`cardio:org-alnylam-pharmaceuticals`)

## Provenance

Content hash: c785dc36c6981a3de13202f647cd094754d9d6627209803308a5672625b37d51
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
